Companion Diagnostics Oncology Market Forecast: NGS Scaling, Liquid Biopsy Growth, and Tumor-Agnostic Testing (2026–2034)
The companion diagnostics (CDx) oncology market is a pivotal enabler of precision cancer care—matching targeted therapies to patients most likely to benefit through biomarker-defined decisions. CDx detect molecular, protein, or genomic features tied to a drug’s efficacy, safety, or optimal use. In oncology, they guide therapy selection and switching as resistance emerges across...
0 Reacties 0 aandelen 63 Views